TRAX (First Tracks Biotherapeutics) Beginning Cash Position: $35.97 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $44.64
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Beginning Cash Position?

First Tracks Biotherapeutics TRAX +1.36% 12 Beginning Cash Position is $35.97 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

First Tracks Biotherapeutics's Beginning Cash Position for the quarter that ended in Dec. 2024 was $35.97 Mil.

First Tracks Biotherapeutics's quarterly Beginning Cash Position increased from . 20 ($0.00 Mil) to Dec. 2023 ($71.31 Mil) but then declined from Dec. 2023 ($71.31 Mil) to Dec. 2024 ($35.97 Mil).

First Tracks Biotherapeutics's annual Beginning Cash Position increased from . 20 ($0.00 Mil) to Dec. 2023 ($71.31 Mil) but then declined from Dec. 2023 ($71.31 Mil) to Dec. 2024 ($35.97 Mil).

First Tracks Biotherapeutics Beginning Cash Position Related Terms

First Tracks Biotherapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Beginning Cash Position Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Beginning Cash Position
71.31 35.97

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Beginning Cash Position 71.31 35.97
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $35.97 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Beginning Cash Position of $35.97 Mil as of Dec. 2024. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Beginning Cash Position too high?
First Tracks Biotherapeutics' current Beginning Cash Position is $35.97 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Beginning Cash Position compare to AVLN and IMTX?
First Tracks Biotherapeutics' Beginning Cash Position of $35.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Beginning Cash Position is $35.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Beginning Cash Position of $35.97 Mil. The current Beginning Cash Position is $35.97 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Beginning Cash Position is $35.97 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.64
Price